Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice

Blood ◽  
2001 ◽  
Vol 98 (6) ◽  
pp. 1852-1857 ◽  
Author(s):  
Kazuya Sato ◽  
Yoshihiro Torimoto ◽  
Yasuaki Tamura ◽  
Motohiro Shindo ◽  
Hitoshi Shinzaki ◽  
...  

Abstract Heat-shock proteins (HSPs) act as molecular chaperones binding endogenous antigenic peptides and transporting them to major histocompatibility complexes. HSPs chaperone a broad repertoire of endogenous peptides including tumor antigens. For the immunotherapy of tumors, a strategy using HSPs may be more advantageous than other procedures because the identification of each tumor-specific antigen is not necessary. In this study, the efficacy of immunotherapy against minimal residual leukemia cells using HSP preparations was evaluated. HSP70 and GP96 were purified from syngeneic leukemia cell line A20 and immunized into BALB/c mice during the reconstitution period of the immune system after syngeneic bone marrow transplantation. In this procedure, all mice not immunized were dead within 60 days of A20 inoculation, whereas the survival times of HSP-immunized mice were significantly prolonged. In addition, the depletion of either CD4+ or CD8+ T lymphocyte significantly abrogated this efficacy, indicating that both CD4+ and CD8+ T lymphocytes were required for tumor cell rejection. Moreover, the vaccination of HSPs elicited a specific response of potent CD8+ T lymphocytes cytotoxic against A20 in vitro. These observations suggest that immunization of the complex of HSPs and peptides derived from leukemia cells leads to immune responses. These immune responses are sufficient to reject minimal amounts of leukemia cells for relatively immunocompromised mice after syngeneic bone marrow transplantation.

Blood ◽  
2014 ◽  
Vol 123 (19) ◽  
pp. 3045-3055 ◽  
Author(s):  
Robert G. Newman ◽  
Michael J. Dee ◽  
Thomas R. Malek ◽  
Eckhard R. Podack ◽  
Robert B. Levy

Key PointsVaccination with lymphoma cells secreting gp96-Ig together with directed IL-2 rapidly elicit effective tumor immunity after syngeneic HSCT. IL-2 cytokine-antibody complex expands CD8+ T lymphocytes and NK cells and enhances pathogen immunity early after HSCT.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4571-4571 ◽  
Author(s):  
Gerardo Lopez-Hernandez ◽  
Norma Lopez-Santiago ◽  
Alberto Olaya-Vargas ◽  
Martín Pérez-García ◽  
Rosa María Nideshda Ramírez-Uribe ◽  
...  

Abstract Background Fanconi anemia (FA) is a condition characterized by congenital malformations, low height, and progressive bone marrow failure during childhood, genomic instability and hypersensitivity to DNA cross-linking agents. Bone marrow transplantation (BMT), is currently the only treatment capable to restore normal hematopoiesis and improve survival of these patients. To achieve a successful allogeneic BMT, a normal T-cell immunity reconstitution is required.1,2 Objective To describe the kinetics of immune reconstitution in six patients with FA after BMT, having used a reduce intensity conditioning regimen, well as associated infections during the post-transplant process. Methods We describe the distribution in peripheral blood of CD3+ T lymphocytes, CD16 +/CD56+ NK cells, CD4+ helper T lymphocytes, CD8+ cytotoxic T lymphocytes and CD19+/CD20+ B cells, in six patients with FA, after BMT from an HLA-matching sibling and complete chimerism, on days +90, +120, +150, +180, +210 and +360. The conditioning regimen employed consisted of fludarabine (Flu) 150 mg/m2, cyclophosphamide 20 mg/kg and rabbit anti-thymocyte globulin (r-ATG) 20 mg/kg. Infection was determined by a positive reaction of the DNA polymerase chain to Cytomegalovirus (CMV), Epstein-Barr virus, Adenovirus and BK virus (BKV), as well as galactomannan antigen and antibodies against Candida sp, or positive bacterial cultures. Results We observed different kinetics regarding the recovery of different lymphocyte subpopulations, starting from day +90. CD16+/CD56+ NK cells recovered first, between days 90 and 120, followed by CD8+ T lymphocytes between day +120 and +150, CD19+/CD20+ B cells between day +180 and +210, and finally, CD4+ T lymphocytes starting from day 210. Five patients presented infection in the post-BMT stage. Four patients before +90, developed CMV infection, based on positive reaction of the CMV polymerase chain. All patient responses to ganciclovir therapy and no CMV disease were documented. The fifth patient presented with meningitis due to Lysteria monocitogenes and BKV hemorrhagic cystitis at day +153; this patient had the diagnosis of chronic-graft versus host disase, and was treated with ampicillin, rifampicin and intravenous immunoglobulin, evolving satisfactorily. All patients remain alive and well. Discussion Most patients in our report developed CMV infection, as being reported with FLU and anti-thymocyte globulin combination. We observed a later reconstitution in comparison with patients in whom lower doses of r-ATG (<10 mg/kg) have been used3. In our group of patients, reconstitution of NK cells and CD8+ T lymphocytes, helped to reduce the frequency of asymptomatic viral infections, as reconstitution of innate immunity and cytotoxic CD8+ T lymphocytes can achieve effective antiviral effector responses, allowing for the control of viral infections, until reconstitution of CD4+ T lymphocytes were fully achieved. The infectious complications associated with this prolonged state of profound immunosuppression and late immune reconstitution, can be attenuated with a closely follow-up for these infectious agents through PCR-mediated detection techniques, which allows an early diagnosis and prompt treatment. Conclusion Immunological reconstitution after a BMT in FA patients is determinant for morbidity and mortality, mainly due to opportunistic infections and GVHD. We observed that recovery kinetics of different lymphocyte populations is different in cases in which higher doses of r-GAT are used, also an early detection and prompt treatment of opportunistic infections may be determinant for patient's survival. Conflict-of-interest disclosure: The authors declare they have nothing to disclose. Correspondence: Gerardo López-Hernández. [email protected] BibliographyOgonek J, Kralj Juric M, Ghimire S, Varanasi PR, Holler E, Greinix H, et al. Immune reconstitution after allogenic hematopoietic stem cell transplantation. Front immunol. 2016; 7 (507):1-15.Smith AR, Wagner JE. Current clinical management of Fanconi anemia. Expert Rev Hematol. 2012; 5 (5): 513-522.Perlingeiro-Beltrame M, Malvezzi M, Bonfim C, Tadeu Covas D, Pasquini R. Immune reconstitution in patients with Fanconi anemia after allogeneic bone marrow transplantation. Cytotherapy. 2014; 0: 1e14. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
1986 ◽  
Vol 68 (4) ◽  
pp. 954-956 ◽  
Author(s):  
A Butturini ◽  
RC Seeger ◽  
RP Gale

Abstract Bone marrow transplantation is usually preceded by intensive chemotherapy and radiation therapy designed to completely eliminate recipient immune-competent cells that might reject the donor bone marrow. We show that seven of 14 bone marrow transplant recipients who received intensive conditioning retained circulating T lymphocytes that proliferate after incubation with interleukin 2 and phytohemagglutinin and function as effector cells in an in vitro model of graft rejection. These T cells may mediate graft rejection.


Blood ◽  
1989 ◽  
Vol 73 (5) ◽  
pp. 1359-1366
Author(s):  
BE Bierer ◽  
SJ Burakoff ◽  
BR Smith

The lymphocyte cell surface molecule CD5 (T1, Leu 1, Tp67 in the human; Ly 1 in the mouse) is expressed on the majority of circulating T lymphocytes and a small population of B cells. We have analyzed CD5 expression on repopulating T cells in the peripheral blood of patients after allogeneic bone marrow transplantation (BMT). The frequency of CD3+ T cells that lack expression of CD5 is dramatically increased after BMT compared with the normal population. The percent of total CD3+ CD5- cells correlated with the presence of graft versus host disease and with time following transplant, but did not correlate with age, diagnosis, preparative regimen, T-cell depletion of the marrow, major histocompatibility complex compatibility, or the presence or absence of interstitial pneumonitis. Furthermore, the total number and percent of CD8+ CD5- cells was increased following BMT. CD3+ cells from BMT patients were sorted for the presence or absence of CD5 expression. CD3+ CD5- cells were capable of interleukin-2 production and of mediating cytolysis following lectin stimulation. We conclude that CD3+ CD5- T cells are functional and represent a significant proportion of circulating cells in patients after BMT.


Blood ◽  
1986 ◽  
Vol 67 (2) ◽  
pp. 444-449 ◽  
Author(s):  
A Fischer ◽  
A Durandy ◽  
JP de Villartay ◽  
E Vilmer ◽  
F Le Deist ◽  
...  

Abstract Eight patients with severe combined immunodeficiency received bone marrow cells from their HLA haplotype-identical fathers after bone marrow T cell depletion by rosetting with neuraminidase-treated sheep red cells. Because the method led to the infusion of a small percentage of T lymphocytes (0.1% to 0.3%), cyclosporin was given by continuous intravenous infusion for two months in order to prevent the occurrence of graft-v-host disease (GVHD). Three patients who did have residual nonfunctional T lymphocytes received busulfan and cyclophosphamide before transplantation. Engraftment was observed in seven patients, and severe GVHD was not seen. Two patients died early after the bone marrow transplantation because of prior infections, and a third died at day 90 from a B cell lymphoproliferative syndrome. The five other patients are doing well. Stable engraftment has been achieved with reconstitution of cell-mediated immunity in 5/5 and humoral immunity in 4/5 patients.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2971-2971
Author(s):  
Xinchun Chen ◽  
Yi Zeng ◽  
Gang Li ◽  
Sylvia Thompson ◽  
Marjan Sepassi ◽  
...  

Abstract We have previously reported that purified tumor derived chaperone-rich cell lysate (CRCL) containing multiple heat shock proteins (HSPs) is a promising cancer vaccine, capable of generating tumor-specific T cell responses and protective immunity in different animal tumor models. In this study, we have explored the therapeutic applicability of CRCL in the context of syngeneic bone marrow transplantation (BMT) to treat preexisting leukemia. BALB/c mice received a 10-fold LD100 dose of bcr-abl+ leukemia cells (12B1) subcutaneously (s.c.) on day -7. On day -1, 900cGy of total body irradiation (TBI) was given followed by syngeneic bone marrow transplantation (BMT) on day 0. Transplanted mice received 20X106 bone marrow cells along with 50X106 splenocytes (SPC) intravenously (i.v.). We have demonstrated that BMT/SPC prolonged survival of mice by a median time of 7 days (median survival time [MST] from tumor inoculation of no BMT versus BMT/SPC =19 vs 26 days), however, all mice eventually died of disseminated leukemia. When recipients received BMT and SPC from syngeneic donors that had been previously immunized with 12B1-derived CRCL (immune BMT/SPC) the MST was increased to 29 days with 26.1% of transplanted mice surviving without tumor (p&lt;0.01 immune BMT/SPC vs naive BMT/SPC). Vaccination of immune BMT/SPC recipients with 20 mg 12B1-derived CRCL in the early post-transplant period (day +1 and day +6) increased MST to 32 days (p&lt;0.01 vs naïve BMT/SPC control) but did not significantly improve overall survival (26.3%) when compared to immune BMT/SPC mice not receiving post transplant 12B1-CRCL vaccine. Eleven to 17 weeks later, mice with no evidence of disease were re-challenged with 12B1 cells in one groin and A20 B cell leukemia cells in the opposite groin. Eighty percent of the mice demonstrated long term tumor specific immunity by rejecting the 12B1 rechallenge while 100% of the mice developed A20 tumors. Our results indicate that CRCL is a promising vaccine that can be used to generate specific anti-tumor immunity that can be effectively transferred to a host via BMT.


Sign in / Sign up

Export Citation Format

Share Document